TELO2

Across TCGA pan-cancer cohorts, TELO2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TELO2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TELO2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TELO2 is over-expressed in tumor, although a few such as COAD and OV show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where TELO2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TELO2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.222	<.001	10	view →
LSCC	Female	II,III,IV	+0.459	<.001	8	view →
HNSC	Male	III,IV	+0.279	<.001	8	view →
COAD	All	All	−0.187	<.001	8	view →
PDAC	Female	II,III,IV	+0.476	.011	5	view →
LUAD	All	All	+0.103	.002	4	view →
OV	All	All	−0.281	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TELO2–CCRCC

Open the CCRCC breakdown →